A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer

2022-502125-17-00 Protocol 1467-0001 Human pharmacology (Phase I) - First administration to humans Ended

Start 16 Oct 2023 · End 11 Apr 2025 · Status Ended · 2 EU/EEA countries · 5 sites · Protocol 1467-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 27
Countries 2
Sites 5

Advanced solid tumors

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
16 Oct 2023 → 11 Apr 2025
Decision date (initial)
2023-09-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-502125-17-00
WHO UTN
U1111-1291-2873

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors

VersionLevelCodeTermSystem organ class
21.0 LLT 10049516 Malignant tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim Espana S.A.

Sponsor organisation
Boehringer Ingelheim Espana S.A.
Address
Carrer Prat De La Riba 50
City
Sant Cugat Del Valles
Postcode
08174
Country
Spain

Locations

2 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 12 4
Sweden Ended 2 1
Rest of world
United States, Canada
13

Investigational sites

Spain

4 sites · Ended
Hospital Clinic De Barcelona
Servicio de Oncología Médica, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario 12 De Octubre
Servicio de Oncología Médica, Bloque D, Avenida De Cordoba S/n, Madrid
Fundacion Instituto Valenciano De Oncologia
Servicio de Oncología Médica, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital Quironsalud Barcelona
Next Oncology Barcelona IOB, Placa D'alfonso Comin 5-7, 08023, Barcelona

Sweden

1 site · Ended
Karolinska University Hospital
Karolinska Comprehensive Cancer Center, Eugeniavagen 3, 171 64, Solna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2023-10-17 2023-11-22 2024-08-14
Sweden 2023-10-16 2023-11-10 2024-08-14

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 2 · Art. 38 CTR

Temporary halt TH-42538

Halt date
2024-08-14
Member states concerned
Sweden
Publication date
2024-08-27
Reason
Study management related, Sponsor decision
Explanation
The protocol defined criteria for enrolment hold have not been met. The decision of temporary hold is based on the recommendation of the Dose Escalation Committee and to perform an analysis of the data for the first ten patients treated with BI 1821736.
Benefit-risk balance changed
No
Treatment stopped
No

Temporary halt TH-42539

Halt date
2024-08-14
Member states concerned
Spain
Publication date
2024-08-27
Reason
Sponsor decision, Study management related
Explanation
The protocol defined criteria for enrolment hold have not been met. The decision of temporary hold is based on the recommendation of the Dose Escalation Committee and to perform an analysis of the data for the first ten patients treated with BI 1821736.
Benefit-risk balance changed
No
Treatment stopped
No

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-30 Spain Acceptable
2023-09-04
2023-09-08
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-01-18 Spain Acceptable
2023-09-04
2024-01-18
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-04-19 Spain Acceptable
2023-09-04
2024-04-19
4 SUBSTANTIAL MODIFICATION SM-1 2024-10-02 Spain Acceptable 2024-11-25
5 SUBSTANTIAL MODIFICATION SM-2 2025-04-24 Spain Acceptable
2025-06-09
2025-06-09